On May 6, 2026, the U.S. Food and Drug Administration (FDA) updated its Portable Ultrasound Device Classification Guidance, requiring all unapproved portable ultrasound devices—including handheld, palm-sized, and battery-powered models—that lack 510(k) or De Novo clearance to prominently label themselves as ‘For Non-Diagnostic Use Only’ on packaging and instructions. Failure to do so triggers automatic reclassification as Class II medical devices, subjecting them to Quality System Regulation (21 CFR Part 820) compliance and pre-import FDA review. This development is highly relevant to manufacturers, exporters, and regulatory affairs professionals in the medical device supply chain—particularly those engaged in OEM/ODM production for U.S. distribution.

Event Overview

The U.S. FDA issued an updated guidance document titled Portable Ultrasound Device Classification Guidance on May 6, 2026. It specifies that any portable ultrasound device not cleared via 510(k) or authorized via De Novo pathway must display the statement ‘For Non-Diagnostic Use Only’ in a conspicuous location on its labeling and accompanying instructions. Devices failing to meet this requirement will be classified as Class II medical devices under FDA regulation, triggering mandatory adherence to the Quality System Regulation (QSR 820) and requiring FDA review prior to importation into the United States.

Industries Affected by Segment

Original Equipment Manufacturers (OEMs) and Original Design Manufacturers (ODMs)

OEM/ODM firms—especially those based in China producing portable ultrasound units for global brands—are directly impacted because their products often enter the U.S. market without individual 510(k) submissions, relying instead on client-led clearances or general-purpose positioning. Under the new guidance, absence of the required non-diagnostic statement renders such devices subject to Class II controls, increasing regulatory burden and potentially halting shipments at U.S. ports.

Medical Device Exporters and Distributors

Exporters handling logistics, customs declarations, and labeling compliance for portable ultrasound devices face immediate operational risk. U.S. Customs and Border Protection (CBP) may detain consignments lacking compliant labeling—even if previously accepted—pending verification of classification status and QSR 820 readiness. This introduces delays, storage costs, and potential re-labeling requirements post-arrival.

Regulatory Affairs and Quality Assurance Teams

Internal regulatory and QA functions must now verify labeling language across all product variants—including firmware screens, quick-start guides, and e-labeling platforms. The guidance applies regardless of intended use claims made verbally or in marketing materials; only the physical or digital labeling determines classification. Teams must assess whether existing documentation meets the ‘conspicuous’ standard defined in FDA’s labeling guidance (e.g., font size, contrast, placement).

Key Actions for Enterprises and Practitioners

Review labeling language across all current SKUs and pending product launches

Manufacturers and exporters should audit all portable ultrasound device labels—including outer cartons, device housings, user manuals, and embedded digital interfaces—to confirm presence, visibility, and consistency of the phrase ‘For Non-Diagnostic Use Only’. Any deviation from FDA’s definition of ‘conspicuous’ may invalidate compliance.

Assess classification status of each model against 510(k)/De Novo pathways

Companies must determine whether each portable ultrasound model has a valid FDA clearance or authorization. If not, the non-diagnostic label is mandatory—and cannot be omitted even if the device is marketed solely for point-of-care training, veterinary applications, or industrial imaging. Classification is determined by FDA, not marketing intent.

Prepare for potential QSR 820 readiness assessments

While the guidance itself does not require immediate facility inspections, automatic Class II classification means affected devices fall under QSR 820 jurisdiction. Firms should ensure documented evidence of design controls, corrective and preventive actions (CAPA), and supplier management systems is available for possible FDA review during import entry or post-market surveillance.

Engage with U.S. importers early to align labeling and documentation workflows

Because labeling responsibility rests with the U.S. owner/operator or initial importer, OEMs and foreign manufacturers should proactively coordinate with their U.S. partners to harmonize label versions, update technical files, and clarify accountability for compliance—especially where branding or multilingual labeling is involved.

Editorial Perspective / Industry Observation

Observably, this guidance reflects FDA’s ongoing effort to close regulatory gaps around rapidly proliferating low-cost, high-functionality portable imaging tools. Analysis shows it is less a sudden enforcement shift and more a formal codification of existing enforcement expectations—reinforcing that ‘intended use’ is defined by labeling and objective functionality, not disclaimers in sales pitches. From an industry perspective, it signals growing scrutiny of software-enabled imaging devices operating outside traditional diagnostic paradigms. Current more appropriate interpretation is that this is a compliance trigger—not yet a widespread enforcement campaign—but one that demands proactive alignment before shipment, not reactive correction after detention.

In summary, the May 6, 2026 FDA guidance establishes a bright-line rule: portable ultrasound devices without FDA clearance must declare non-diagnostic status in labeling—or accept Class II regulatory obligations. For affected enterprises, the priority is not speculation about future policy, but verification, documentation, and coordination across the supply chain. This is best understood not as a new barrier, but as a clarified threshold for market access.

Source: U.S. FDA, Portable Ultrasound Device Classification Guidance, issued May 6, 2026. No further implementation timeline or transitional provisions have been published as of the guidance release date. Ongoing monitoring of FDA’s Medical Device Guidance Documents webpage and Federal Register updates is recommended.